Introducing Our Fully Validated Preclinical In Vivo Schizophrenia Model
Feb 11 2013
As part of our ongoing development program in the areas of neurology and psychiatry, we are pleased to introduce an updated and fully validated preclinical in vivo model for the study of compounds and therapies aimed at combating the cognitive and negative symptoms of schizophrenia.
This model’s study paradigm is based on the administration of PCP, and the main cognitive tasks are Morris Water Maze (MWM) and Novel Object Recognition (NOR), as well as the Prepulse Inhibition (PPI) of startle for the PCP-induced disruption. The model also displays measurable deficits in social behavior. The schizophrenic-like symptoms induced by PCP are reversed by marketed anti-psychotic compound(s).
This newly validated animal model also offers investigators the opportunity to examine a full battery of histopathological endpoints and biomarkers within the study, along with advanced in vivo imaging such as PET-CT/SPECT-CT and MRI/MRS.
For more information on this study model, as well as any other neurologic or psychiatric study model offered by Charles River, please contact us at 1.877.CRIVER.1 or askcharlesriver@crl.com.
Related Information